Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 744-748

  Den Hollander, Jan G ^a,b   Mouton, Johan W ^a   Verbrugh, Henri A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Zuiderziekenhuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; DRUG EFFICACY; DRUG INHIBITION; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT PLANNING;

EID: 0031955902     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.744     Document Type: Article

References (34)

1. Barclay, M. L., E. J. Begg, S. T. Chambers, and D. R. Boswell. 1995. Improved efficacy with nonsimultancous administration of first doses of gentamicin and ceftazidime in vitro. Antimicrob. Agents Chemother. 39:132-136.
2. Berenbaum, M. C. 1978. A method for testing synergy with any number of agents. J. Infect. Dis. 137:122-130.
3. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
5. Chandrasekar, P. H., L. R. Crane, and E. J. Bailey. 1987. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J. Antimicrob. Chemother. 19:321-329.
6. Chin, N. X., and H. C. Neu. 1983. Synergy of azlocillin with aminoglycosides. J. Antimicrob. Chemother. 11(Suppl. B):33-38.
7. Den Hollander, J. G., A. M. Horrevorts, M. P. J. van Goor, H. A. Verbrugh, and J. W. Mouton. 1997. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 41:95-100.
8. 7a. Den Hollander, J. G., J. W. Mouton, and H. A. Verbrugh. 1997. Pharmacodynamic parameters of combination therapy based on fractional inhibitory kinetics, abstr. A-21a, p. 5. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Drusano, G. L., M. Prichard, P. A. Bilello, and J. A. Bilello. 1996. Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Antimicrob. Agents Chemother. 40:1143-1147.
10. Dudley, M. N., and S. H. Zinner. 1991. Single daily dosing of amikacin in an in-vitro model. J. Antimicrob. Chemother. 27(Suppl. C):15-19.
11. Elion, G. B., S. Singer, and G. H. Hitchings. 1953. Antagonists of nucleic acid derivates. VIlI. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
12. Graphpad Software Inc. 1990. Instat 2 program manual. Graphpad Software Inc., San Diego, Calif.
13. Guggenblicher, J. P., F. Allerberger, M. P. Dierich, R. Schmitzberger, and E. Semenitz. 1988. Spaced administration of antibiotic combinations to eliminate Pseudomonas from sputum in cystic fibrosis. Lancet ii:749-750.
14. Hallander, K. O., K. Dornbusch, L. Gezelius, K. Jacobson, and I. Karlsson. 1982. Synergism between aminoglycosidcs and cephalosporins with antipseudomonal activity: index and killing curve method. Antimicrob. Agents Chemother. 22:743-752.
15. Horrevorts, A. M., C. M. de Ridder, M. C. Pool, M. J. A. de Jonge, J. E. Degener, G. Djoljic-Danilovic, M. F. Michel, and K. F. Kerrebijn. 1987. Checkerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index. J. Antimicrob. Chemother. 19:119-125.
16. Horrevorts, A. M., M. F. Michel, and K. F. Kerrebijn. 1987. Antibiotic interaction: interpretation of fractional inhibitory and fractional bactericidal concentration indices. Eur. J. Clin. Microbiol. 4:502-503.
17. Kapusnik, J. E., C. J. Hackbarth, H. F. Chambers, T. Carpenter, and M. A. Sande. 1988. Single, large daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J. Infect. Dis. 158: 7-12.
18. König, P., J. P. Guggenblicher, E. Semenitz, and W. Foisner. 1986. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. Chemotherapy (Basel) 32:44-58.
19. Mordenti, J. J., R. Quintiliani, and C. H. Nightingale. 1985. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J. Antimicrob. Chemother. 15 (Suppl. A):313-321.
20. Mouton, J. W., A. M. Horrevorts, P. H. G. Mulder, E. P. Prens, and M. F. Michel. 1990. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusion in healthy volunteers. Antimicrob. Agents Chemother. 34:2307-2311.
21. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
22. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. Nicolau, D. P., C. D. Freeman, P. B. Belliveau, C. H. Nightingale, J. W. Ross, and R. Quintiliani. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
24. Norden, C. W., H. Wentzel, and E. Keleti. 1979. Comparison of techniques for measurement of in vitro synergism. J. Infect. Dis. 140:692-733.
25. Reyes, M. P., F. Smith, and A. M. Lerner. 1984. Studies of in vitro synergy between several beta-lactam and aminoglycoside antibiotics against endocarditis strains of Pseudomonas aeruginosa. J. Infect. 8:110-117.
26. Ritschel, W. A. 1982. Compartment models, p. 199-218. In W. A. Ritschel (ed.), Handbook of basic pharmacokinetics, 2nd ed. Drug Intelligence Publications Inc., Hamilton, Ill.
27. SAS Institute Inc. 1990. SAS user's guide. SAS Institute Inc., Cary, N.C.
28. Stratton, C. W., and R. C. Cooksey. 1991. Susceptibility tests: special tests, p. 1153-1166. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
29. Ter Braak, E. W., P. J. de Vries, K. P. Bouter, S. G. van der Vegt, G. C. Dorrestein, J. W. Nortier, A. van Dijh, R. P. Verkooyen, and H. A. Verbrugh. 1990. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: a comparative trial with netilmicin plus ceftriaxone. Am. J. Med. 89:58-66.
30. Van de Klundert, J. A. M., J. S. Vliegenthart, E. van Doorn, G. P. A. Bongaerts, L. Molendijk, and R. P. Mouton. 1984. A simple method for identification of aminoglycoside-modifying enzymes. J. Antimicrob. Chemother. 14:339-348.
31. Van de Klundert, J. A. M., M. H. van Gestel, E. van Doorn, and R. P. Mouton. 1986. Disc diffusion test for determination of semi-quantitative substrate profiles of β-lactamases. J. Antimicrob. Chemother. 17:471-479.
32. Vogelman, B., and W. A. Craig. 1986. Kinetics of antimicrobial activity. J. Pediatr. 108:835-840.
33. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
34. White, R. L., D. S. Burgess, M. Manduru, and J. A. Bosso. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checker-board, and E test. Antimicrob. Agents Chemother. 40:1914-1918.